[
  {
    "title": "海翔药业(002099.SZ)第三季度净利润3545.45万元、同比增长119.47%",
    "href": "http://stock.jrj.com.cn/2022/10/30200337097822.shtml",
    "datetime": "2022-10-30 20:03:34",
    "code": "002099"
  },
  {
    "title": "海翔药业：拟约3亿元台州市投建总部研究院",
    "href": "http://stock.jrj.com.cn/2022/09/26172937022049.shtml",
    "datetime": "2022-09-26 17:29:32",
    "code": "002099"
  },
  {
    "title": "海翔药业(002099.SZ)半年度净利润1.72亿元 同比增长183.71%",
    "href": "http://stock.jrj.com.cn/2022/08/30165636953044.shtml",
    "datetime": "2022-08-30 16:56:15",
    "code": "002099"
  },
  {
    "title": "海翔药业2022年上半年预计净利1.6亿-2亿 同比增加164%-231% 医药业务销售订单饱满",
    "href": "http://stock.jrj.com.cn/2022/07/11203136800341.shtml",
    "datetime": "2022-07-11 20:31:47",
    "code": "002099"
  },
  {
    "title": "A股异动 | 海翔药业涨6%股价创3个月新高 医药业务销售订单饱满 业绩预增超2倍",
    "href": "http://stock.jrj.com.cn/2022/07/11101236798023.shtml",
    "datetime": "2022-07-11 10:12:41",
    "code": "002099"
  },
  {
    "title": "医药业务销售订单饱满，海翔药业(002099.SZ)上半年净利预增164.43%-230.54%",
    "href": "http://stock.jrj.com.cn/2022/07/10170536797025.shtml",
    "datetime": "2022-07-10 17:05:49",
    "code": "002099"
  },
  {
    "title": "海翔药业：上半年净利预增164.43%-230.54%",
    "href": "http://stock.jrj.com.cn/2022/07/10154236796893.shtml",
    "datetime": "2022-07-10 15:42:08",
    "code": "002099"
  },
  {
    "title": "海翔药业领投，华益泰康完成近亿元B+轮融资",
    "href": "http://stock.jrj.com.cn/2022/06/29144436767657.shtml",
    "datetime": "2022-06-29 14:44:24",
    "code": "002099"
  },
  {
    "title": "海翔药业(002099.SZ)2021年年度权益分派10派1元 股权登记日5月24日",
    "href": "http://stock.jrj.com.cn/2022/05/17173736655607.shtml",
    "datetime": "2022-05-17 17:37:19",
    "code": "002099"
  },
  {
    "title": "海翔药业：与鑫开元签署战略合作协议，协议期限为20年",
    "href": "http://stock.jrj.com.cn/2022/05/16104936650340.shtml",
    "datetime": "2022-05-16 10:49:14",
    "code": "002099"
  },
  {
    "title": "海翔药业(002099.SZ)与鑫开元签署战略合作协议",
    "href": "http://stock.jrj.com.cn/2022/05/15165336649226.shtml",
    "datetime": "2022-05-15 16:53:10",
    "code": "002099"
  },
  {
    "title": "海翔药业2022年第一季度净利8702.42万同比增长52.17% 员工持股计划摊销减少",
    "href": "http://stock.jrj.com.cn/2022/05/03185036546073.shtml",
    "datetime": "2022-05-03 18:50:47",
    "code": "002099"
  },
  {
    "title": "海翔药业(002099.SZ)：一季度净利升52.17%至8702.42万元",
    "href": "http://stock.jrj.com.cn/2022/04/25170936464422.shtml",
    "datetime": "2022-04-25 17:09:10",
    "code": "002099"
  },
  {
    "title": "海翔药业(002099.SZ)：2021年净利降70.21%至9522.96万元 拟10派1元",
    "href": "http://stock.jrj.com.cn/2022/04/22193236430979.shtml",
    "datetime": "2022-04-22 19:32:33",
    "code": "002099"
  },
  {
    "title": "海翔药业(002099.SZ)业绩快报：2021年净利降68.22%至1.02亿元",
    "href": "http://stock.jrj.com.cn/2022/03/29202736156418.shtml",
    "datetime": "2022-03-29 20:27:27",
    "code": "002099"
  },
  {
    "title": "海翔药业(002099.SZ)：一季度净利润预增50%-80%",
    "href": "http://stock.jrj.com.cn/2022/03/29202536156427.shtml",
    "datetime": "2022-03-29 20:25:05",
    "code": "002099"
  },
  {
    "title": "【龙虎榜】海翔药业2月16日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/02/16180434370431.shtml",
    "datetime": "2022-02-16 18:04:11",
    "code": "002099"
  },
  {
    "title": "海翔药业于上海成立新公司 注册资本4.5亿",
    "href": "http://stock.jrj.com.cn/2022/02/09134834312955.shtml",
    "datetime": "2022-02-09 13:48:59",
    "code": "002099"
  },
  {
    "title": "海翔药业2021年预计净利9500万-1.3亿同比下降59%-70% 上半年原材料价格大幅上涨",
    "href": "http://stock.jrj.com.cn/2022/01/30095234258689.shtml",
    "datetime": "2022-01-30 09:52:47",
    "code": "002099"
  },
  {
    "title": "海翔药业拟对碧林实业增资2000万 增资完成后持股34%",
    "href": "http://stock.jrj.com.cn/2022/01/28223134251176.shtml",
    "datetime": "2022-01-28 22:31:55",
    "code": "002099"
  },
  {
    "title": "海翔药业(002099.SZ)：与华益泰康签署战略合作协议",
    "href": "http://stock.jrj.com.cn/2022/01/03173234110719.shtml",
    "datetime": "2022-01-03 17:32:49",
    "code": "002099"
  },
  {
    "title": "海翔药业：与华益泰康签署战略合作协议 共同建设CDMO服务平台",
    "href": "http://stock.jrj.com.cn/2022/01/03164034109938.shtml",
    "datetime": "2022-01-03 16:40:11",
    "code": "002099"
  },
  {
    "title": "海翔药业投资设立全资子公司拟购买土地使用权并投资建设湖北医药化工综合生产基地项目 总投资额约20亿",
    "href": "http://stock.jrj.com.cn/2021/11/30223233946295.shtml",
    "datetime": "2021-11-30 22:32:17",
    "code": "002099"
  },
  {
    "title": "海翔药业(002099.SZ)：拟投资20亿元建湖北医药化工综合生产基地项目",
    "href": "http://stock.jrj.com.cn/2021/11/30190033945318.shtml",
    "datetime": "2021-11-30 19:00:18",
    "code": "002099"
  },
  {
    "title": "海翔药业(002099.SZ)：聘请陈芬儿院士为公司首席科学家",
    "href": "http://stock.jrj.com.cn/2021/11/28161833929574.shtml",
    "datetime": "2021-11-28 16:18:51",
    "code": "002099"
  },
  {
    "title": "海翔药业：聘请陈芬儿院士为公司首席科学家",
    "href": "http://stock.jrj.com.cn/2021/11/28160633929558.shtml",
    "datetime": "2021-11-28 16:06:19",
    "code": "002099"
  },
  {
    "title": "海翔药业(002099.SZ)：2020年员工持股计划第一个锁定期将于11月19日届满",
    "href": "http://stock.jrj.com.cn/2021/11/17160033866326.shtml",
    "datetime": "2021-11-17 16:00:00",
    "code": "002099"
  },
  {
    "title": "海翔药业(002099.SZ)：第三季度净利降83.23%至1615.43万元",
    "href": "http://stock.jrj.com.cn/2021/10/26194233756498.shtml",
    "datetime": "2021-10-26 19:42:10",
    "code": "002099"
  },
  {
    "title": "海翔药业2021年前三季度预计净利7000万-9000万下降75%-81% 原材料价格上涨",
    "href": "http://stock.jrj.com.cn/2021/08/30204433354962.shtml",
    "datetime": "2021-08-30 20:44:54",
    "code": "002099"
  },
  {
    "title": "海翔药业：员工持股计划摊销金额较大 前三季度净利同比预降75.13%至80.66%",
    "href": "http://stock.jrj.com.cn/2021/08/30190733354698.shtml",
    "datetime": "2021-08-30 19:07:09",
    "code": "002099"
  },
  {
    "title": "海翔药业2021年半年度净利6050.67万元 同比净利减少77.22%",
    "href": "http://stock.jrj.com.cn/2021/08/30183333353635.shtml",
    "datetime": "2021-08-30 18:33:32",
    "code": "002099"
  },
  {
    "title": "海翔药业(002099.SZ)前三季度扣非净利预降28.42%-33.95%",
    "href": "http://stock.jrj.com.cn/2021/08/30182033353562.shtml",
    "datetime": "2021-08-30 18:20:35",
    "code": "002099"
  },
  {
    "title": "海翔药业(002099.SZ)上半年净利降77.22%至6050.67万元",
    "href": "http://stock.jrj.com.cn/2021/08/30181733353537.shtml",
    "datetime": "2021-08-30 18:17:45",
    "code": "002099"
  },
  {
    "title": "控股股东减持3000万股 海翔药业业绩难逃进三步退两步“魔咒”",
    "href": "http://stock.jrj.com.cn/2021/07/28081533162645.shtml",
    "datetime": "2021-07-28 08:15:00",
    "code": "002099"
  },
  {
    "title": "海翔药业(002099.SZ)：控股股东大宗交易减持1.85%股份",
    "href": "http://stock.jrj.com.cn/2021/07/27172033158734.shtml",
    "datetime": "2021-07-27 17:20:50",
    "code": "002099"
  },
  {
    "title": "海翔药业2021年上半年预计净利5800万-7500万下降72%-78% 原材料价格上涨",
    "href": "http://stock.jrj.com.cn/2021/07/14211533096709.shtml",
    "datetime": "2021-07-14 21:15:44",
    "code": "002099"
  },
  {
    "title": "海翔药业(002099.SZ)：参设私募投资基金完成备案手续",
    "href": "http://stock.jrj.com.cn/2021/06/29221633017924.shtml",
    "datetime": "2021-06-29 22:16:08",
    "code": "002099"
  },
  {
    "title": "海翔药业：2020年度公司CDMO/CMO业务实现营业收入2.35亿元 公司暂不涉及CRO业务",
    "href": "http://stock.jrj.com.cn/2021/06/08093932891636.shtml",
    "datetime": "2021-06-08 09:39:03",
    "code": "002099"
  },
  {
    "title": "海翔药业拟出资1亿元参与设立合伙企业投资复宏汉霖",
    "href": "http://stock.jrj.com.cn/2021/06/04212432875866.shtml",
    "datetime": "2021-06-04 21:24:15",
    "code": "002099"
  },
  {
    "title": "海翔药业(002099.SZ)2020年度权益分派10派0.2元 股权登记日为6月10日",
    "href": "http://stock.jrj.com.cn/2021/06/04205732875785.shtml",
    "datetime": "2021-06-04 20:57:47",
    "code": "002099"
  },
  {
    "title": "海翔药业(002099.SZ)：拟出资1亿元参设合伙企业 以投资复宏汉霖",
    "href": "http://stock.jrj.com.cn/2021/06/04205632875784.shtml",
    "datetime": "2021-06-04 20:56:21",
    "code": "002099"
  },
  {
    "title": "海翔药业：1亿元参设基金投资复宏汉霖",
    "href": "http://stock.jrj.com.cn/2021/06/04200132875563.shtml",
    "datetime": "2021-06-04 20:01:17",
    "code": "002099"
  },
  {
    "title": "【龙虎榜】海翔药业5月27日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2021/05/27180432830941.shtml",
    "datetime": "2021-05-27 18:04:22",
    "code": "002099"
  },
  {
    "title": "海翔药业股价闪崩跌停",
    "href": "http://stock.jrj.com.cn/2021/05/27134732828970.shtml",
    "datetime": "2021-05-27 13:47:25",
    "code": "002099"
  },
  {
    "title": "海翔药业：公司子公司台州振港18500吨染料项目正在按计划推进",
    "href": "http://stock.jrj.com.cn/2021/04/08154632332333.shtml",
    "datetime": "2021-04-08 15:46:23",
    "code": "002099"
  },
  {
    "title": "海翔药业：公司染料板块的生产经营正按计划有序开展",
    "href": "http://stock.jrj.com.cn/2021/03/24160732208814.shtml",
    "datetime": "2021-03-24 16:07:54",
    "code": "002099"
  },
  {
    "title": "海翔药业2020年预计净利2.8亿-3.3亿同比下降63.67%-57.19% 市场需求减弱",
    "href": "http://stock.jrj.com.cn/2021/01/30171631815245.shtml",
    "datetime": "2021-01-30 17:16:40",
    "code": "002099"
  },
  {
    "title": "海翔药业(002099.SZ)：盐酸克林霉素胶囊通过仿制药一致性评价",
    "href": "http://stock.jrj.com.cn/2021/01/18185231716578.shtml",
    "datetime": "2021-01-18 18:52:07",
    "code": "002099"
  },
  {
    "title": "海翔药业(002099.SZ)：公司及全资子公司通过高新技术企业认定",
    "href": "http://stock.jrj.com.cn/2021/01/17164731706498.shtml",
    "datetime": "2021-01-17 16:47:57",
    "code": "002099"
  },
  {
    "title": "海翔药业(002099.SZ)：实控人王云富解除质押7722万股",
    "href": "http://stock.jrj.com.cn/2020/12/30191231606325.shtml",
    "datetime": "2020-12-30 19:12:37",
    "code": "002099"
  },
  {
    "title": "聚焦生命科学 产学研齐头并进 助力企业创新发展",
    "href": "http://stock.jrj.com.cn/2020/12/21225331539213.shtml",
    "datetime": "2020-12-21 22:53:03",
    "code": "002099"
  },
  {
    "title": "携手多方涉足疫苗研发 海翔药业医药板块添活力",
    "href": "http://stock.jrj.com.cn/2020/11/21003331326473.shtml",
    "datetime": "2020-11-21 00:33:10",
    "code": "002099"
  },
  {
    "title": "海翔药业：产业基金参与疫苗研发合作",
    "href": "http://stock.jrj.com.cn/2020/11/16180131293231.shtml",
    "datetime": "2020-11-16 18:01:43",
    "code": "002099"
  },
  {
    "title": "【龙虎榜】海翔药业11月12日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2020/11/12180531268822.shtml",
    "datetime": "2020-11-12 18:05:35",
    "code": "002099"
  },
  {
    "title": "海翔药业2020年前三季度净利3.62亿下滑47.55% 营业外收入同比下滑",
    "href": "http://stock.jrj.com.cn/2020/10/27095331140216.shtml",
    "datetime": "2020-10-27 09:53:57",
    "code": "002099"
  },
  {
    "title": "海翔药业2020年上半年净利2.66亿下滑46.43% 医药板块一季度开工不足",
    "href": "http://stock.jrj.com.cn/2020/08/27143930604130.shtml",
    "datetime": "2020-08-27 14:39:26",
    "code": "002099"
  },
  {
    "title": "海翔药业上半年净利预减半 子公司环境违法被停止生产",
    "href": "http://stock.jrj.com.cn/2020/08/24164730576845.shtml",
    "datetime": "2020-08-24 16:47:00",
    "code": "002099"
  },
  {
    "title": "海翔药业2020年上半年预计净利2.48亿元–2.73亿元同比下降 下游纺织、印染企业需求低迷",
    "href": "http://stock.jrj.com.cn/2020/07/15101430247597.shtml",
    "datetime": "2020-07-15 10:14:14",
    "code": "002099"
  },
  {
    "title": "海翔药业：2020年半年度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2020/07/15083030245875.shtml",
    "datetime": "2020-07-15 08:30:10",
    "code": "002099"
  },
  {
    "title": "海翔药业对外投资设立产业基金 合伙企业计划募集规模10.01亿元",
    "href": "http://stock.jrj.com.cn/2020/07/06211430155846.shtml",
    "datetime": "2020-07-06 21:14:18",
    "code": "002099"
  },
  {
    "title": "海翔药业：拟10亿元参设医药大健康产业基金",
    "href": "http://stock.jrj.com.cn/2020/07/06194330155387.shtml",
    "datetime": "2020-07-06 19:43:57",
    "code": "002099"
  },
  {
    "title": "海翔药业聘任孙杨为公司总经理",
    "href": "http://stock.jrj.com.cn/2020/05/18191829704356.shtml",
    "datetime": "2020-05-18 19:18:43",
    "code": "002099"
  },
  {
    "title": "海翔药业2020年一季度净利1.05亿下滑48.08% 疫情影响导致销售订单交货减少",
    "href": "http://stock.jrj.com.cn/2020/04/30190529434111.shtml",
    "datetime": "2020-04-30 19:05:21",
    "code": "002099"
  },
  {
    "title": "海翔药业：2020年第一季度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2020/04/02002029172041.shtml",
    "datetime": "2020-04-02 00:20:02",
    "code": "002099"
  },
  {
    "title": "海翔药业2020年一季度预计净利9000万元–1.1亿元 同比下降46%-56%",
    "href": "http://stock.jrj.com.cn/2020/04/01210729171149.shtml",
    "datetime": "2020-04-01 21:07:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：一季度净利同比预降45.67%至55.55%",
    "href": "http://stock.jrj.com.cn/2020/04/01173529169622.shtml",
    "datetime": "2020-04-01 17:35:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：一季度净利同比预降46%-56%",
    "href": "http://stock.jrj.com.cn/2020/04/01170129169299.shtml",
    "datetime": "2020-04-01 17:01:38",
    "code": "002099"
  },
  {
    "title": "海翔药业：订购的口罩自动化设备预计3月中旬到位",
    "href": "http://stock.jrj.com.cn/2020/03/10100128989373.shtml",
    "datetime": "2020-03-10 10:01:00",
    "code": "002099"
  },
  {
    "title": "海翔药业 药厂还是化工厂？",
    "href": "http://stock.jrj.com.cn/2020/02/18154028848686.shtml",
    "datetime": "2020-02-18 15:40:57",
    "code": "002099"
  },
  {
    "title": "海翔药业：加强防疫工作 订购自动化设备自产口罩",
    "href": "http://stock.jrj.com.cn/2020/02/10143428802851.shtml",
    "datetime": "2020-02-10 14:34:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：全年赚7.7亿同比增近三成 单季利润下降需关注",
    "href": "http://stock.jrj.com.cn/2020/02/05073728773346.shtml",
    "datetime": "2020-02-05 07:37:10",
    "code": "002099"
  },
  {
    "title": "海翔药业：2019年年度报告主要财务指标及分配预案",
    "href": "http://stock.jrj.com.cn/2020/01/22210028722751.shtml",
    "datetime": "2020-01-22 21:00:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：2019年净利润同比增长27.4% 拟10派3元",
    "href": "http://stock.jrj.com.cn/2020/01/22163528721252.shtml",
    "datetime": "2020-01-22 16:35:15",
    "code": "002099"
  },
  {
    "title": "海翔药业：2019年净利同比增27% 拟10派3元",
    "href": "http://stock.jrj.com.cn/2020/01/22163328721254.shtml",
    "datetime": "2020-01-22 16:33:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：2019年净利同比增长27% 拟10派3元",
    "href": "http://stock.jrj.com.cn/2020/01/22163128721246.shtml",
    "datetime": "2020-01-22 16:31:33",
    "code": "002099"
  },
  {
    "title": "海翔药业6名股东合计减持201万股 套现约1537万元",
    "href": "http://stock.jrj.com.cn/2020/01/01231628614309.shtml",
    "datetime": "2020-01-01 23:16:14",
    "code": "002099"
  },
  {
    "title": "海翔药业股东东港投资减持1740万股 套现约1.13亿元",
    "href": "http://stock.jrj.com.cn/2019/12/19221228559685.shtml",
    "datetime": "2019-12-19 22:12:59",
    "code": "002099"
  },
  {
    "title": "海翔药业：控股股东大宗交易减持1.07%股份",
    "href": "http://stock.jrj.com.cn/2019/12/19183828557977.shtml",
    "datetime": "2019-12-19 18:38:05",
    "code": "002099"
  },
  {
    "title": "海翔药业：收到日本PMDA适合性调查结果通知书",
    "href": "http://stock.jrj.com.cn/2019/11/20165228427498.shtml",
    "datetime": "2019-11-20 16:52:21",
    "code": "002099"
  },
  {
    "title": "海翔药业：全资子公司川南药业通过美国FDA现场检查",
    "href": "http://stock.jrj.com.cn/2019/11/11174228380770.shtml",
    "datetime": "2019-11-11 17:42:41",
    "code": "002099"
  },
  {
    "title": "海翔药业闯关一致性评价 申报药品进入优先评审公示期",
    "href": "http://stock.jrj.com.cn/2019/11/01162928339421.shtml",
    "datetime": "2019-11-01 16:29:00",
    "code": "002099"
  },
  {
    "title": "海翔药业第三季度盈利1.94亿 同比下滑6.21%",
    "href": "http://stock.jrj.com.cn/2019/10/27215628305891.shtml",
    "datetime": "2019-10-27 21:56:40",
    "code": "002099"
  },
  {
    "title": "海翔药业对外投资参与设立合伙企业",
    "href": "http://stock.jrj.com.cn/2019/08/21081128008311.shtml",
    "datetime": "2019-08-21 08:11:38",
    "code": "002099"
  },
  {
    "title": "海翔药业：拟出资2000万元参与设立寓鑫投资 储备培育优质项目资源",
    "href": "http://stock.jrj.com.cn/2019/08/20184028005998.shtml",
    "datetime": "2019-08-20 18:40:27",
    "code": "002099"
  },
  {
    "title": "海翔药业：2019年前三季度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2019/08/20180028005782.shtml",
    "datetime": "2019-08-20 18:00:02",
    "code": "002099"
  },
  {
    "title": "海翔药业：上半年净利4.96亿元 同比增长80%",
    "href": "http://stock.jrj.com.cn/2019/08/20175228005748.shtml",
    "datetime": "2019-08-20 17:52:05",
    "code": "002099"
  },
  {
    "title": "海翔药业上半年净利同比增长80% 前三季度预盈6.7亿元-7.5亿元",
    "href": "http://stock.jrj.com.cn/2019/08/20175128005747.shtml",
    "datetime": "2019-08-20 17:51:08",
    "code": "002099"
  },
  {
    "title": "海翔药业：上半年净利同比增长80% 前三季度预盈6.7亿元-7.5亿元",
    "href": "http://stock.jrj.com.cn/2019/08/20174728005760.shtml",
    "datetime": "2019-08-20 17:47:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：前三季度净利预增39%-55%",
    "href": "http://stock.jrj.com.cn/2019/08/20174328005685.shtml",
    "datetime": "2019-08-20 17:43:17",
    "code": "002099"
  },
  {
    "title": "海翔药业2019年上半年净利4.96亿 医药板块国际高端市场销售增长",
    "href": "http://stock.jrj.com.cn/2019/08/20174228005693.shtml",
    "datetime": "2019-08-20 17:42:13",
    "code": "002099"
  },
  {
    "title": "海翔药业9名股东拟减持股份 预计合计减持不超总股本0.28%",
    "href": "http://stock.jrj.com.cn/2019/06/10190927681840.shtml",
    "datetime": "2019-06-10 19:09:36",
    "code": "002099"
  },
  {
    "title": "新荣记老板内幕交易被罚1.3亿 海翔药业季报波动显著",
    "href": "http://stock.jrj.com.cn/2019/05/10154127554226.shtml",
    "datetime": "2019-05-10 15:41:05",
    "code": "002099"
  },
  {
    "title": "15家药企晒半年度成绩单：海翔药业净利增幅最高达81%",
    "href": "http://stock.jrj.com.cn/2019/05/10020127550174.shtml",
    "datetime": "2019-05-10 02:01:15",
    "code": "002099"
  },
  {
    "title": "海翔药业：2019年半年度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2019/04/22225027457977.shtml",
    "datetime": "2019-04-22 22:50:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：一季度净利增352% 上半年净利预增63%-81%",
    "href": "http://stock.jrj.com.cn/2019/04/22212027457180.shtml",
    "datetime": "2019-04-22 21:20:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：预计上半年盈利4.5亿-5亿元",
    "href": "http://stock.jrj.com.cn/2019/04/22202527456757.shtml",
    "datetime": "2019-04-22 20:25:55",
    "code": "002099"
  },
  {
    "title": "海翔药业：2018年净利2.02亿元 同比增长352%",
    "href": "http://stock.jrj.com.cn/2019/04/22202427456755.shtml",
    "datetime": "2019-04-22 20:24:00",
    "code": "002099"
  },
  {
    "title": "一季度修正后净利润预增324%-369% 海翔药业涨停",
    "href": "http://stock.jrj.com.cn/2019/04/09143027354141.shtml",
    "datetime": "2019-04-09 14:30:55",
    "code": "002099"
  },
  {
    "title": "海翔药业：2019年第一季度业绩报告预告(修正公告)",
    "href": "http://stock.jrj.com.cn/2019/04/08203027347986.shtml",
    "datetime": "2019-04-08 20:30:00",
    "code": "002099"
  },
  {
    "title": "年报首批社保基金持仓曝光 连续4个季度坚守海翔药业东诚药业",
    "href": "http://stock.jrj.com.cn/2019/02/21092527069767.shtml",
    "datetime": "2019-02-21 09:25:00",
    "code": "002099"
  },
  {
    "title": "年报首批社保基金持仓曝光 连续4个季度坚守2股",
    "href": "http://stock.jrj.com.cn/2019/02/21010727068479.shtml",
    "datetime": "2019-02-21 01:07:51",
    "code": "002099"
  },
  {
    "title": "海翔药业去年净利6.05亿同比增长77% 董事长孙杨年薪98万",
    "href": "http://stock.jrj.com.cn/2019/02/18220827057058.shtml",
    "datetime": "2019-02-18 22:08:00",
    "code": "002099"
  },
  {
    "title": "海翔药业2018年净赚6亿同比增77% 计划现金分红4.7亿",
    "href": "http://stock.jrj.com.cn/2019/02/18150127055509.shtml",
    "datetime": "2019-02-18 15:01:47",
    "code": "002099"
  },
  {
    "title": "年报净利同比增77%+一季报净利预增 海翔药业涨停",
    "href": "http://stock.jrj.com.cn/2019/02/18095727054257.shtml",
    "datetime": "2019-02-18 09:57:46",
    "code": "002099"
  },
  {
    "title": "海翔药业：年报净利同比增77% 2019年一季度净利预增257%-307%",
    "href": "http://stock.jrj.com.cn/hotstock/2019/02/18080027053777.shtml",
    "datetime": "2019-02-18 08:00:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：拟合作投建新型染料化工现代化综合性生产基地",
    "href": "http://stock.jrj.com.cn/hotstock/2019/02/18080027053770.shtml",
    "datetime": "2019-02-18 08:00:00",
    "code": "002099"
  },
  {
    "title": "公告精选：紫光学大终止重大资产重组；海翔药业2018年净利同比增77%",
    "href": "http://stock.jrj.com.cn/2019/02/17185527051449.shtml",
    "datetime": "2019-02-17 18:55:00",
    "code": "002099"
  },
  {
    "title": "数家药企2018年业绩报喜 海翔药业净利同比增逾76%",
    "href": "http://stock.jrj.com.cn/2019/02/17180627051406.shtml",
    "datetime": "2019-02-17 18:06:00",
    "code": "002099"
  },
  {
    "title": "海翔药业年报业绩增长76.79%",
    "href": "http://stock.jrj.com.cn/2019/02/17164827051298.shtml",
    "datetime": "2019-02-17 16:48:58",
    "code": "002099"
  },
  {
    "title": "海翔药业：2018年年度报告主要财务指标及分配预案",
    "href": "http://stock.jrj.com.cn/2019/02/17164027051294.shtml",
    "datetime": "2019-02-17 16:40:02",
    "code": "002099"
  },
  {
    "title": "海翔药业：2019年第一季度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2019/02/17164027051290.shtml",
    "datetime": "2019-02-17 16:40:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：2018年净利同比增77%",
    "href": "http://stock.jrj.com.cn/2019/02/17163427051285.shtml",
    "datetime": "2019-02-17 16:34:06",
    "code": "002099"
  },
  {
    "title": "海翔药业：2018年净利同比增77% 今年一季度净利预增257%-307%",
    "href": "http://stock.jrj.com.cn/2019/02/17162527051270.shtml",
    "datetime": "2019-02-17 16:25:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：累计回购逾3%股份 耗资2.38亿元",
    "href": "http://stock.jrj.com.cn/hotstock/2018/12/17080026751996.shtml",
    "datetime": "2018-12-17 08:00:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：回购股份比例达3% 耗资2.38亿元",
    "href": "http://stock.jrj.com.cn/2018/12/14161626742071.shtml",
    "datetime": "2018-12-14 16:16:00",
    "code": "002099"
  },
  {
    "title": "89家药企发布年报业绩预告 七成公司预喜",
    "href": "http://stock.jrj.com.cn/2018/11/02012425294769.shtml",
    "datetime": "2018-11-02 01:24:47",
    "code": "002099"
  },
  {
    "title": "海翔药业回购股份达总股本2% 最高成交价5.57元/股",
    "href": "http://stock.jrj.com.cn/2018/10/29131425271914.shtml",
    "datetime": "2018-10-29 13:14:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：回购金额拟增至不超5亿元",
    "href": "http://stock.jrj.com.cn/hotstock/2018/10/17075925214289.shtml",
    "datetime": "2018-10-17 07:59:59",
    "code": "002099"
  },
  {
    "title": "海翔药业：前三季净利4.83亿元 同比增69%",
    "href": "http://stock.jrj.com.cn/hotstock/2018/10/17075925214287.shtml",
    "datetime": "2018-10-17 07:59:59",
    "code": "002099"
  },
  {
    "title": "海翔药业：2018年前三季度报告主要财务指标",
    "href": "http://stock.jrj.com.cn/2018/10/16212025211806.shtml",
    "datetime": "2018-10-16 21:20:00",
    "code": "002099"
  },
  {
    "title": "海翔药业回购金额拟增至不超5亿元",
    "href": "http://stock.jrj.com.cn/2018/10/16194925211587.shtml",
    "datetime": "2018-10-16 19:49:20",
    "code": "002099"
  },
  {
    "title": "海翔药业：前三季净利同比增69% 回购金额拟增至不超5亿元",
    "href": "http://stock.jrj.com.cn/2018/10/16191525211451.shtml",
    "datetime": "2018-10-16 19:15:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：2018年年度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2018/10/16183025211281.shtml",
    "datetime": "2018-10-16 18:30:05",
    "code": "002099"
  },
  {
    "title": "[海翔药业]国家药监局:建立来源可查、去向可追的药品信息化追溯体系",
    "href": "http://stock.jrj.com.cn/2018/10/12000025196320.shtml",
    "datetime": "2018-10-12 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]新型四环素获FDA专家肯定,有望10月获批",
    "href": "http://stock.jrj.com.cn/2018/10/10000025196319.shtml",
    "datetime": "2018-10-10 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]未来最畅销的孤儿药TOP10排行预测(2018-2024)",
    "href": "http://stock.jrj.com.cn/2018/10/09000025196318.shtml",
    "datetime": "2018-10-09 00:00:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：已累计回购逾2500万股 耗资1.28亿元",
    "href": "http://stock.jrj.com.cn/hotstock/2018/10/08075925167969.shtml",
    "datetime": "2018-10-08 07:59:53",
    "code": "002099"
  },
  {
    "title": "[海翔药业]进了医保的高端仿制药,患者为何买不到",
    "href": "http://stock.jrj.com.cn/2018/10/08000025196317.shtml",
    "datetime": "2018-10-08 00:00:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：已累计回购近1.28亿元股份",
    "href": "http://stock.jrj.com.cn/2018/10/07163025164052.shtml",
    "datetime": "2018-10-07 16:30:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]人民日报:让一致性评价药真正替代原研",
    "href": "http://stock.jrj.com.cn/2018/09/30000025166436.shtml",
    "datetime": "2018-09-30 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]70%市场将给一致性评价药 !",
    "href": "http://stock.jrj.com.cn/2018/09/29000025166435.shtml",
    "datetime": "2018-09-29 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]研发新知识:0期临床试验",
    "href": "http://stock.jrj.com.cn/2018/09/28000025166441.shtml",
    "datetime": "2018-09-28 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]重大利好!药品从申报到实验,最多60天",
    "href": "http://stock.jrj.com.cn/2018/09/27000025166442.shtml",
    "datetime": "2018-09-27 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]美国疫苗安全制度对我国的启示",
    "href": "http://stock.jrj.com.cn/2018/09/25000025166439.shtml",
    "datetime": "2018-09-25 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]CNDA | 组织对所有疫苗生产企业飞行检查",
    "href": "http://stock.jrj.com.cn/2018/09/20000025120098.shtml",
    "datetime": "2018-09-20 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]孟加拉国制药企业期待与中国更紧密合作",
    "href": "http://stock.jrj.com.cn/2018/09/19000025120097.shtml",
    "datetime": "2018-09-19 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]北大教授李玲:印度的仿制药是学习中国的经验,中国缺少国家层面的药价谈判",
    "href": "http://stock.jrj.com.cn/2018/09/18000025120096.shtml",
    "datetime": "2018-09-18 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]写意论坛丨国际规范下生物药全生命周期质量管理",
    "href": "http://stock.jrj.com.cn/2018/09/17000025120099.shtml",
    "datetime": "2018-09-17 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]秒懂!创新药专利布局是一场攻防战",
    "href": "http://stock.jrj.com.cn/2018/09/13000025092241.shtml",
    "datetime": "2018-09-13 00:00:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：近期培南系列产品价格上涨约5%-15%",
    "href": "http://stock.jrj.com.cn/2018/09/12090525080046.shtml",
    "datetime": "2018-09-12 09:05:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]国家药监局:4批41个品规仿制药通过一致性评价",
    "href": "http://stock.jrj.com.cn/2018/09/12000025092238.shtml",
    "datetime": "2018-09-12 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]国产创新药迎来机遇期",
    "href": "http://stock.jrj.com.cn/2018/09/11000025092239.shtml",
    "datetime": "2018-09-11 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]优时比创新药物优普洛在华获批",
    "href": "http://stock.jrj.com.cn/2018/09/10000025092240.shtml",
    "datetime": "2018-09-10 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]我国实施eCTD情况以及面临的挑战",
    "href": "http://stock.jrj.com.cn/2018/09/06000025058568.shtml",
    "datetime": "2018-09-06 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]反直觉!将细菌进行基因改造能替代药物对抗疾病吗",
    "href": "http://stock.jrj.com.cn/2018/09/05000025058564.shtml",
    "datetime": "2018-09-05 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]Solid Bio宣布FDA解除SGT-001的临床试验暂停状态",
    "href": "http://stock.jrj.com.cn/2018/09/04000025058566.shtml",
    "datetime": "2018-09-04 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]国家药监局详解我国境外新药审批新进展",
    "href": "http://stock.jrj.com.cn/2018/09/03000025058562.shtml",
    "datetime": "2018-09-03 00:00:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：2018年前三季度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2018/08/30110025024451.shtml",
    "datetime": "2018-08-30 11:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]加快药品治理能力现代化步伐⑧ | 提速保质 全力推进一致性评价检查工作",
    "href": "http://stock.jrj.com.cn/2018/08/30000025026288.shtml",
    "datetime": "2018-08-30 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]浅析BCS分类与制剂的联系",
    "href": "http://stock.jrj.com.cn/2018/08/29000025026287.shtml",
    "datetime": "2018-08-29 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]一致性评价将加速医药市场重塑 减少医保基金支出",
    "href": "http://stock.jrj.com.cn/2018/08/24000025026285.shtml",
    "datetime": "2018-08-24 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]FDA批准Argenx公司的Efgartigimod针对重症肌无力的三期临床试验",
    "href": "http://stock.jrj.com.cn/2018/08/23000025026286.shtml",
    "datetime": "2018-08-23 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]意外失败!IDO+PD1黑色素瘤III期研究提前终止",
    "href": "http://stock.jrj.com.cn/2018/08/22000024985479.shtml",
    "datetime": "2018-08-22 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]怎么才算精密量取",
    "href": "http://stock.jrj.com.cn/2018/08/21000024985480.shtml",
    "datetime": "2018-08-21 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]药用辅料,行业规范成趋势",
    "href": "http://stock.jrj.com.cn/2018/08/20000024975847.shtml",
    "datetime": "2018-08-20 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]成本恐再涨!环境部通过新规,原料药企或被强制投保",
    "href": "http://stock.jrj.com.cn/2018/08/16000024975848.shtml",
    "datetime": "2018-08-16 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]最新!国家药监、卫健委联合发布:创新药上市审批再提速,进口药品注册申请再简化",
    "href": "http://stock.jrj.com.cn/2018/08/15000024975846.shtml",
    "datetime": "2018-08-15 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]中国制药创新火热,监管如何营造有利环境NIH、EMA、ICH专家给了建议",
    "href": "http://stock.jrj.com.cn/2018/08/14000024975850.shtml",
    "datetime": "2018-08-14 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]国家药监二十二条细则加密审评审批信息,医药人可以安心搞研发啦!",
    "href": "http://stock.jrj.com.cn/2018/08/13000024975849.shtml",
    "datetime": "2018-08-13 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]创新药企大利好!新规发布强化药品审评审批保密制度",
    "href": "http://stock.jrj.com.cn/2018/08/10000024939015.shtml",
    "datetime": "2018-08-10 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]国家药品监督管理局关于加强化学仿制药注射剂注册申请现场检查工作的公告(2018年第20号)",
    "href": "http://stock.jrj.com.cn/2018/08/09000024939013.shtml",
    "datetime": "2018-08-09 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]武田收购Shire,全球药企TOP10排名生变",
    "href": "http://stock.jrj.com.cn/2018/08/08000024939016.shtml",
    "datetime": "2018-08-08 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]成本恐再涨!环境部通过新规,原料药企或被强制投保",
    "href": "http://stock.jrj.com.cn/2018/08/07000024939012.shtml",
    "datetime": "2018-08-07 00:00:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：已累计回购1.04%股份 耗资8682万元",
    "href": "http://stock.jrj.com.cn/hotstock/2018/08/06080024908946.shtml",
    "datetime": "2018-08-06 08:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]国家药监局召开专题会研究器械审评审批改革思路举措",
    "href": "http://stock.jrj.com.cn/2018/08/06000024939014.shtml",
    "datetime": "2018-08-06 00:00:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：已累计回购1687万股 耗资8682万元",
    "href": "http://stock.jrj.com.cn/2018/08/03170524902825.shtml",
    "datetime": "2018-08-03 17:05:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：累计回购1686.8万股",
    "href": "http://stock.jrj.com.cn/2018/08/03165124902755.shtml",
    "datetime": "2018-08-03 16:51:32",
    "code": "002099"
  },
  {
    "title": "[海翔药业]台州市委副书记、代市长张晓强莅临前进化工调研",
    "href": "http://stock.jrj.com.cn/2018/07/31000024884201.shtml",
    "datetime": "2018-07-31 00:00:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：美国FDA解除公司外沙厂区进口警示",
    "href": "http://stock.jrj.com.cn/2018/07/17155024825497.shtml",
    "datetime": "2018-07-17 15:50:30",
    "code": "002099"
  },
  {
    "title": "海翔药业：子公司瓯华化工通过园区复产审核",
    "href": "http://stock.jrj.com.cn/2018/07/12133124805337.shtml",
    "datetime": "2018-07-12 13:31:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]药政 | FDA仿制药资料提交和评估的相关指导文件",
    "href": "http://stock.jrj.com.cn/2018/07/06000024827202.shtml",
    "datetime": "2018-07-06 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]FDA局长:总统预算请求再次给FDA拨款以促进制药创新和通过药品价格竞争扩大患者使用",
    "href": "http://stock.jrj.com.cn/2018/07/04000024828100.shtml",
    "datetime": "2018-07-04 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]市场监管总局局长张茅:逐步实现新药上市审评审批时间缩短至2-3年",
    "href": "http://stock.jrj.com.cn/2018/07/03000024828099.shtml",
    "datetime": "2018-07-03 00:00:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：2018年半年度业绩报告预告(修正公告)",
    "href": "http://stock.jrj.com.cn/2018/07/02181024757461.shtml",
    "datetime": "2018-07-02 18:10:00",
    "code": "002099"
  },
  {
    "title": "午间公告：海翔药业上调业绩预告 任子行中期业绩预增50%-80%",
    "href": "http://stock.jrj.com.cn/2018/07/02122024756091.shtml",
    "datetime": "2018-07-02 12:20:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]药用原辅料进口通关出新规,这些重点需要你知道",
    "href": "http://stock.jrj.com.cn/2018/07/02000024828098.shtml",
    "datetime": "2018-07-02 00:00:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：环保趋严产品提价业绩弹性扩大",
    "href": "http://stock.jrj.com.cn/2018/06/05090024637689.shtml",
    "datetime": "2018-06-05 09:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]标准物质使用中十大常见问题",
    "href": "http://stock.jrj.com.cn/2018/05/31000024620042.shtml",
    "datetime": "2018-05-31 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]ECA新闻:检查员工艺验证备忘—详细分析",
    "href": "http://stock.jrj.com.cn/2018/05/30000024620043.shtml",
    "datetime": "2018-05-30 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]原料药出口50强优势何在",
    "href": "http://stock.jrj.com.cn/2018/05/29000024620041.shtml",
    "datetime": "2018-05-29 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]FDA的RTF信对新药上市影响多大",
    "href": "http://stock.jrj.com.cn/2018/05/28000024620044.shtml",
    "datetime": "2018-05-28 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]仿制药新政让中国仿制药质量上得去市场推得开",
    "href": "http://stock.jrj.com.cn/2018/05/25000024590936.shtml",
    "datetime": "2018-05-25 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]原辅料进口通关征求意见!一致性评价提升进口原辅料需求",
    "href": "http://stock.jrj.com.cn/2018/05/24000024590937.shtml",
    "datetime": "2018-05-24 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]FDA发布促进新兴技术用于制药创新的行业指南",
    "href": "http://stock.jrj.com.cn/2018/05/23000024590934.shtml",
    "datetime": "2018-05-23 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]想和 CDE 沟通你家产品吗CFDA 新政策了解一下",
    "href": "http://stock.jrj.com.cn/2018/05/21000024590935.shtml",
    "datetime": "2018-05-21 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]FDA表示将改变各类指南类文件的撰写文风",
    "href": "http://stock.jrj.com.cn/2018/05/18000024559418.shtml",
    "datetime": "2018-05-18 00:00:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：首次回购公司股份150万股",
    "href": "http://stock.jrj.com.cn/hotstock/2018/05/17075924551527.shtml",
    "datetime": "2018-05-17 07:59:58",
    "code": "002099"
  },
  {
    "title": "[海翔药业]化药注射剂一致性评价 实力型企业争抢先发优势",
    "href": "http://stock.jrj.com.cn/2018/05/17000024559419.shtml",
    "datetime": "2018-05-17 00:00:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：首次回购股份150万股",
    "href": "http://stock.jrj.com.cn/2018/05/16221024550232.shtml",
    "datetime": "2018-05-16 22:10:00",
    "code": "002099"
  },
  {
    "title": "医药股再度爆发 海翔药业等6股涨停",
    "href": "http://stock.jrj.com.cn/2018/05/16105024547072.shtml",
    "datetime": "2018-05-16 10:50:25",
    "code": "002099"
  },
  {
    "title": "“吃药”行情持续 海翔药业盘中涨停",
    "href": "http://stock.jrj.com.cn/2018/05/16104524547004.shtml",
    "datetime": "2018-05-16 10:45:07",
    "code": "002099"
  },
  {
    "title": "[海翔药业]原料药在注射剂一致性评价中的关键作用",
    "href": "http://stock.jrj.com.cn/2018/05/16000024549520.shtml",
    "datetime": "2018-05-16 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]总局首次公告适用ICH指导原则 接轨国际标准",
    "href": "http://stock.jrj.com.cn/2018/05/15000024549519.shtml",
    "datetime": "2018-05-15 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]2017年我国原料药外贸业绩创新高",
    "href": "http://stock.jrj.com.cn/2018/05/14000024549521.shtml",
    "datetime": "2018-05-14 00:00:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：子公司瓯华化工临时停产",
    "href": "http://stock.jrj.com.cn/2018/05/13190024531758.shtml",
    "datetime": "2018-05-13 19:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]欧盟委员会发布前沿药品GMP指南",
    "href": "http://stock.jrj.com.cn/2018/05/11000024527121.shtml",
    "datetime": "2018-05-11 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]回顾:食药监改革20年,CFDA不会拆分",
    "href": "http://stock.jrj.com.cn/2018/05/10000024527123.shtml",
    "datetime": "2018-05-10 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]中国孤儿药市场开发与投资机会分析",
    "href": "http://stock.jrj.com.cn/2018/05/09000024514831.shtml",
    "datetime": "2018-05-09 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]289目录国内特有品种一致性评价 抱团才有戏",
    "href": "http://stock.jrj.com.cn/2018/05/08000024514825.shtml",
    "datetime": "2018-05-08 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]恒瑞「吸入用地氟烷」获FDA批准,在美国首仿上市",
    "href": "http://stock.jrj.com.cn/2018/05/07000024514830.shtml",
    "datetime": "2018-05-07 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]CFDA大改革:药品可能要与卫计委、民政部合并^",
    "href": "http://stock.jrj.com.cn/2018/05/04000024514827.shtml",
    "datetime": "2018-05-04 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]预判:预计2018年上市的10个重磅仿制药",
    "href": "http://stock.jrj.com.cn/2018/05/03000024514829.shtml",
    "datetime": "2018-05-03 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]川南药业为身患重疾职工开展募捐活动",
    "href": "http://stock.jrj.com.cn/2018/05/02000024480669.shtml",
    "datetime": "2018-05-02 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]国内上市药企业绩分析 谁是2017业绩王",
    "href": "http://stock.jrj.com.cn/2018/05/02000024514828.shtml",
    "datetime": "2018-05-02 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]前进化工启动开展公司级“安全生产月”活动",
    "href": "http://stock.jrj.com.cn/2018/05/02000024480670.shtml",
    "datetime": "2018-05-02 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]椒江区委书记陈挺晨莅临我司调研党建工作",
    "href": "http://stock.jrj.com.cn/2018/05/02000024479911.shtml",
    "datetime": "2018-05-02 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]方法开发报告应该怎么写",
    "href": "http://stock.jrj.com.cn/2018/04/28000024476214.shtml",
    "datetime": "2018-04-28 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]数据驱动临床试验的真实性",
    "href": "http://stock.jrj.com.cn/2018/04/27000024466639.shtml",
    "datetime": "2018-04-27 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]2020版药典拟制修订这些药辅标准",
    "href": "http://stock.jrj.com.cn/2018/04/26000024457629.shtml",
    "datetime": "2018-04-26 00:00:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：2018年半年度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2018/04/24200024442577.shtml",
    "datetime": "2018-04-24 20:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]国家药监总局公布2018立法计划",
    "href": "http://stock.jrj.com.cn/2018/04/24000024440246.shtml",
    "datetime": "2018-04-24 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]辉瑞第三代ALK抑制剂lorlatinib申请上市,获FDA优先审评",
    "href": "http://stock.jrj.com.cn/2018/04/23000024432497.shtml",
    "datetime": "2018-04-23 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]药品网络销售监督管理办法征求意见!网售处方药需探索“中国方案",
    "href": "http://stock.jrj.com.cn/2018/04/18000024415864.shtml",
    "datetime": "2018-04-18 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]抗癌“神药”PD1:你想知道的,都在这里",
    "href": "http://stock.jrj.com.cn/2018/04/17000024401673.shtml",
    "datetime": "2018-04-17 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]原料药生产中的过程分析技术",
    "href": "http://stock.jrj.com.cn/2018/04/16000024401671.shtml",
    "datetime": "2018-04-16 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]2018这些新药聚焦全球目光!",
    "href": "http://stock.jrj.com.cn/2018/04/13000024401670.shtml",
    "datetime": "2018-04-13 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]药物制剂开发中对晶型的考虑",
    "href": "http://stock.jrj.com.cn/2018/04/12000024401672.shtml",
    "datetime": "2018-04-12 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]原料药生产中的过程分析技术",
    "href": "http://stock.jrj.com.cn/2018/04/10000024374216.shtml",
    "datetime": "2018-04-10 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]2018这些新药聚焦全球目光!",
    "href": "http://stock.jrj.com.cn/2018/04/09000024374214.shtml",
    "datetime": "2018-04-09 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]药物制剂开发中对晶型的考虑",
    "href": "http://stock.jrj.com.cn/2018/04/08000024374215.shtml",
    "datetime": "2018-04-08 00:00:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：2017年净利润3.42亿元 同比增长52.08%",
    "href": "http://stock.jrj.com.cn/2018/04/04110024350078.shtml",
    "datetime": "2018-04-04 11:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]巴斯夫、陶氏化学、朗盛、万华等企业2月份产品开始涨价!最高涨幅20%",
    "href": "http://stock.jrj.com.cn/2018/03/28000024314578.shtml",
    "datetime": "2018-03-28 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]一致性评价 88 个受理号最新动态,全在这里了",
    "href": "http://stock.jrj.com.cn/2018/03/27000024314577.shtml",
    "datetime": "2018-03-27 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]289目录19个“国内特有品种“名单发布!需重做临床试验",
    "href": "http://stock.jrj.com.cn/2018/03/26000024314576.shtml",
    "datetime": "2018-03-26 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]关联审评新动态",
    "href": "http://stock.jrj.com.cn/2018/03/22000024314574.shtml",
    "datetime": "2018-03-22 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]淘汰强度多大注射剂再评价四大猜想",
    "href": "http://stock.jrj.com.cn/2018/03/20000024266606.shtml",
    "datetime": "2018-03-20 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]FDA:根据临床相关性建立杂质接受标准作为NDAs、ANDAs和BLAs规范的一部分",
    "href": "http://stock.jrj.com.cn/2018/03/16000024266604.shtml",
    "datetime": "2018-03-16 00:00:00",
    "code": "002099"
  },
  {
    "title": "海翔药业:未能竞得浙江新东港药业45%股权",
    "href": "http://stock.jrj.com.cn/2018/03/12125024226657.shtml",
    "datetime": "2018-03-12 12:50:55",
    "code": "002099"
  },
  {
    "title": "[海翔药业]临床试验登记数创近年新高!2018研发竞赛新格局:哪些产品抢进度",
    "href": "http://stock.jrj.com.cn/2018/03/05000024218881.shtml",
    "datetime": "2018-03-05 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]药监局政策",
    "href": "http://stock.jrj.com.cn/2018/02/28000024172970.shtml",
    "datetime": "2018-02-28 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]CFDA:加大通过一致性评价品种飞检力度!严防一致性评价变“一次性”评价",
    "href": "http://stock.jrj.com.cn/2018/02/27000024172969.shtml",
    "datetime": "2018-02-27 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]一致性评价LOGO好处多大首批品种逐个算",
    "href": "http://stock.jrj.com.cn/2018/02/25000024150064.shtml",
    "datetime": "2018-02-25 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]FDA加强药品生产检查与注册审评的融合",
    "href": "http://stock.jrj.com.cn/2018/02/24000024150066.shtml",
    "datetime": "2018-02-24 00:00:00",
    "code": "002099"
  },
  {
    "title": "拟不超3亿元回购股份 海翔药业涨停",
    "href": "http://stock.jrj.com.cn/2018/02/13094824113113.shtml",
    "datetime": "2018-02-13 09:48:39",
    "code": "002099"
  },
  {
    "title": "[海翔药业]2017版FDA速释口服固体制剂BE豁免指南内容的调整变化",
    "href": "http://stock.jrj.com.cn/2018/02/13000024150059.shtml",
    "datetime": "2018-02-13 00:00:00",
    "code": "002099"
  },
  {
    "title": "多家公司拟回购股份 海翔药业拟回购不超3亿元",
    "href": "http://stock.jrj.com.cn/2018/02/12231724109557.shtml",
    "datetime": "2018-02-12 23:17:11",
    "code": "002099"
  },
  {
    "title": "[海翔药业]2017年中国注册化药申报分析报告",
    "href": "http://stock.jrj.com.cn/2018/02/11000024101235.shtml",
    "datetime": "2018-02-11 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]“两票制”生产企业认定标准将统一,全国总代或消失!",
    "href": "http://stock.jrj.com.cn/2018/02/09000024101234.shtml",
    "datetime": "2018-02-09 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]药品上市提速契机:“未满足临床需求”范围大,最佳突破点在哪",
    "href": "http://stock.jrj.com.cn/2018/02/08000024101236.shtml",
    "datetime": "2018-02-08 00:00:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：参与竞拍新东港药业45%股权",
    "href": "http://stock.jrj.com.cn/2018/02/06173524071659.shtml",
    "datetime": "2018-02-06 17:35:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：子公司川南药业通过FDA认证",
    "href": "http://stock.jrj.com.cn/2018/02/05191024065076.shtml",
    "datetime": "2018-02-05 19:10:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]289目录哪些产品将自然淘汰",
    "href": "http://stock.jrj.com.cn/2018/02/01000024064673.shtml",
    "datetime": "2018-02-01 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]四大热词总结2017中药行业重磅政策与企业大动作",
    "href": "http://stock.jrj.com.cn/2018/01/31000024064671.shtml",
    "datetime": "2018-01-31 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]印仿制药企因质量问题受FDA警告",
    "href": "http://stock.jrj.com.cn/2018/01/29000024028509.shtml",
    "datetime": "2018-01-29 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]GMP从认证到检查第三方服务价值将凸显",
    "href": "http://stock.jrj.com.cn/2018/01/26000024010956.shtml",
    "datetime": "2018-01-26 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]27道问题!一致性评价官方答疑最全汇总",
    "href": "http://stock.jrj.com.cn/2018/01/24000023998578.shtml",
    "datetime": "2018-01-24 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]孙亚洲:原辅料、药包材、制剂企业合作共赢的新时代到来了 | 专家解读关联审评新政",
    "href": "http://stock.jrj.com.cn/2018/01/16000023962635.shtml",
    "datetime": "2018-01-16 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]信立泰专利挑战成功-阿斯利康替格瑞洛晶型专利被宣告全部无效",
    "href": "http://stock.jrj.com.cn/2018/01/15000023949287.shtml",
    "datetime": "2018-01-15 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]临床研究监查:原始资料从“核查”到“审核”",
    "href": "http://stock.jrj.com.cn/2018/01/12000023938681.shtml",
    "datetime": "2018-01-12 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]总局关于调整原料药、药用辅料和药包材审评审批事项的公告(2017年第146号)",
    "href": "http://stock.jrj.com.cn/2018/01/11000023932346.shtml",
    "datetime": "2018-01-11 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]GMP认证即将走下历史舞台!解读",
    "href": "http://stock.jrj.com.cn/2018/01/10000023923101.shtml",
    "datetime": "2018-01-10 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]药用辅料关联审批催DMF加速落地",
    "href": "http://stock.jrj.com.cn/2017/12/29000023872020.shtml",
    "datetime": "2017-12-29 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]修订 36条改革措施有法可依",
    "href": "http://stock.jrj.com.cn/2017/12/05000023742510.shtml",
    "datetime": "2017-12-05 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]修订,取消GMP/GSP认证",
    "href": "http://stock.jrj.com.cn/2017/12/04000023742509.shtml",
    "datetime": "2017-12-04 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]药品注册管理办法(修订稿)征求意见!十种情形不批上市",
    "href": "http://stock.jrj.com.cn/2017/12/01000023734920.shtml",
    "datetime": "2017-12-01 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]“玻璃人”用药市场两大亮点:中国增长潜力巨大,一大拨突破性重磅新药储备",
    "href": "http://stock.jrj.com.cn/2017/11/30000023718554.shtml",
    "datetime": "2017-11-30 00:00:00",
    "code": "002099"
  },
  {
    "title": "海翔药业可转债被否 市场不欢迎只知道伸手要钱的人",
    "href": "http://stock.jrj.com.cn/2017/11/29153523714088.shtml",
    "datetime": "2017-11-29 15:35:32",
    "code": "002099"
  },
  {
    "title": "海翔药业发债募资12.47亿再折戟",
    "href": "http://stock.jrj.com.cn/2017/11/29080223711189.shtml",
    "datetime": "2017-11-29 08:02:13",
    "code": "002099"
  },
  {
    "title": "[海翔药业]收藏:仿制药原研处方查询方法",
    "href": "http://stock.jrj.com.cn/2017/11/29000023718555.shtml",
    "datetime": "2017-11-29 00:00:00",
    "code": "002099"
  },
  {
    "title": "证监会：5家公司可转债过会 海翔药业可转债遭否",
    "href": "http://stock.jrj.com.cn/2017/11/27205523703172.shtml",
    "datetime": "2017-11-27 20:55:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]“放管服”改革CFDA清理规范性文件:废止7件,修改2件",
    "href": "http://stock.jrj.com.cn/2017/11/27000023718553.shtml",
    "datetime": "2017-11-27 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]恒瑞核心品种「盐酸右美托咪定注射液」获FDA批准上市",
    "href": "http://stock.jrj.com.cn/2017/10/23000023274936.shtml",
    "datetime": "2017-10-23 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]2020年版药典,增订品种800个",
    "href": "http://stock.jrj.com.cn/2017/10/11000023256073.shtml",
    "datetime": "2017-10-11 00:00:00",
    "code": "002099"
  },
  {
    "title": "日兴生物：海翔药业计划减持全部公司股份",
    "href": "http://stock.jrj.com.cn/2017/09/26210523172915.shtml",
    "datetime": "2017-09-26 21:05:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]ICH指南汇总",
    "href": "http://stock.jrj.com.cn/2017/09/15000023256048.shtml",
    "datetime": "2017-09-15 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]实验记录的书写规范(药学分析部分)",
    "href": "http://stock.jrj.com.cn/2017/08/21000024625272.shtml",
    "datetime": "2017-08-21 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]GMP检查不会取消的八个理由",
    "href": "http://stock.jrj.com.cn/2017/07/24000023256074.shtml",
    "datetime": "2017-07-24 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]重磅!首个国产PCSK9单抗获批临床",
    "href": "http://stock.jrj.com.cn/2017/07/20000023256075.shtml",
    "datetime": "2017-07-20 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]“两票制”进入执行关键期:完整梳理各地政策,细看四大特征",
    "href": "http://stock.jrj.com.cn/2017/07/14000023255922.shtml",
    "datetime": "2017-07-14 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]罕见病用药三大利好,孤儿药仿制药会否率先破冰",
    "href": "http://stock.jrj.com.cn/2017/07/10000023256019.shtml",
    "datetime": "2017-07-10 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]厉害了!国内第一个口服紫杉醇制剂申报临床",
    "href": "http://stock.jrj.com.cn/2017/07/07000023256021.shtml",
    "datetime": "2017-07-07 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]大手笔!杨森10亿美元引进临床前口服IL-23R拮抗剂",
    "href": "http://stock.jrj.com.cn/2017/06/05000023256046.shtml",
    "datetime": "2017-06-05 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]不惧失败!默沙东再次引进临床前阿尔茨海默病新药",
    "href": "http://stock.jrj.com.cn/2017/06/02000023256047.shtml",
    "datetime": "2017-06-02 00:00:00",
    "code": "002099"
  },
  {
    "title": "[哈药股份]海翔药业终止定增拟发可转债募资12.47亿",
    "href": "http://stock.jrj.com.cn/2017/05/16000031006556.shtml",
    "datetime": "2017-05-16 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]“突破性疗法认定”实施5年 罗氏成最大赢家",
    "href": "http://stock.jrj.com.cn/2017/05/12000023256020.shtml",
    "datetime": "2017-05-12 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]审评审批加速 最快7个月",
    "href": "http://stock.jrj.com.cn/2017/05/11000023256022.shtml",
    "datetime": "2017-05-11 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]干货:原料药的FDA注册",
    "href": "http://stock.jrj.com.cn/2017/04/01000023255975.shtml",
    "datetime": "2017-04-01 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]2020版中国药典重点增加药用辅料标准",
    "href": "http://stock.jrj.com.cn/2017/03/22000023255999.shtml",
    "datetime": "2017-03-22 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]阿法替尼获批上市,优先审评加速海外新药登陆中国",
    "href": "http://stock.jrj.com.cn/2017/02/27000023255973.shtml",
    "datetime": "2017-02-27 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]2016全球畅销药Top 10:“药王”争夺战新看点",
    "href": "http://stock.jrj.com.cn/2017/02/21000023255947.shtml",
    "datetime": "2017-02-21 00:00:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：公司制剂生产线通过国内GMP认证",
    "href": "http://stock.jrj.com.cn/hotstock/2017/02/06080022026205.shtml",
    "datetime": "2017-02-06 08:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]一致性评价13条禁令公布!药企如何冲关",
    "href": "http://stock.jrj.com.cn/2017/01/25000023255921.shtml",
    "datetime": "2017-01-25 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]首批289一致性评价品种,1/3将从市场消失",
    "href": "http://stock.jrj.com.cn/2017/01/23000023255919.shtml",
    "datetime": "2017-01-23 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]CFDA整体公布上市品种“国家药品编码本位码”,可用于编制追溯码",
    "href": "http://stock.jrj.com.cn/2017/01/22000023255920.shtml",
    "datetime": "2017-01-22 00:00:00",
    "code": "002099"
  },
  {
    "title": "[海翔药业]审评提速!1.1类新药,8个月就拿到临床批件,医药行业坐享改革红利",
    "href": "http://stock.jrj.com.cn/2017/01/12000023255974.shtml",
    "datetime": "2017-01-12 00:00:00",
    "code": "002099"
  },
  {
    "title": "海翔药业：拟募资13.75亿元用于染料产业升级配套项目",
    "href": "http://stock.jrj.com.cn/2016/12/18212621852895.shtml",
    "datetime": "2016-12-18 21:26:01",
    "code": "002099"
  },
  {
    "title": "海翔药业定增不超过1亿股获证监会批复",
    "href": "http://stock.jrj.com.cn/2016/06/07160421046932.shtml",
    "datetime": "2016-06-07 16:04:08",
    "code": "002099"
  },
  {
    "title": "海翔药业：公司制剂生产线通过欧盟GMP认证",
    "href": "http://stock.jrj.com.cn/2016/01/27235820496569.shtml",
    "datetime": "2016-01-27 23:58:39",
    "code": "002099"
  },
  {
    "title": "海翔药业拟1亿元投资精细化学企业",
    "href": "http://stock.jrj.com.cn/2016/01/11200720393118.shtml",
    "datetime": "2016-01-11 20:07:21",
    "code": "002099"
  },
  {
    "title": "海翔药业拟定增募资20亿元",
    "href": "http://stock.jrj.com.cn/2015/08/17032619655774.shtml",
    "datetime": "2015-08-17 03:26:15",
    "code": "002099"
  },
  {
    "title": "海翔药业定增逾20亿元 加码医药和染料双主业",
    "href": "http://stock.jrj.com.cn/2015/08/16183419655310.shtml",
    "datetime": "2015-08-16 18:34:48",
    "code": "002099"
  },
  {
    "title": "通鼎光电、柘中建设、海翔药业临时停牌",
    "href": "http://stock.jrj.com.cn/2014/08/28093217901890.shtml",
    "datetime": "2014-08-28 09:32:41",
    "code": "002099"
  },
  {
    "title": "海翔药业重组申请获恢复审核",
    "href": "http://stock.jrj.com.cn/2014/07/07174717556737.shtml",
    "datetime": "2014-07-07 17:47:29",
    "code": "002099"
  },
  {
    "title": "证监会调查海翔药业重组事件",
    "href": "http://stock.jrj.com.cn/2014/06/10071917371940.shtml",
    "datetime": "2014-06-10 07:19:03",
    "code": "002099"
  },
  {
    "title": "海翔药业跌停 资产重组申请被暂停审核",
    "href": "http://stock.jrj.com.cn/2014/06/09100317365490.shtml",
    "datetime": "2014-06-09 10:03:00",
    "code": "002099"
  },
  {
    "title": "海翔药业重组被暂停审核",
    "href": "http://stock.jrj.com.cn/2014/06/09064917363103.shtml",
    "datetime": "2014-06-09 06:49:02",
    "code": "002099"
  },
  {
    "title": "海翔药业新老东家齐否认赌博传闻",
    "href": "http://stock.jrj.com.cn/2014/05/16032317215854.shtml",
    "datetime": "2014-05-16 03:23:35",
    "code": "002099"
  },
  {
    "title": "海翔药业被“贱卖”的疑点",
    "href": "http://stock.jrj.com.cn/2014/05/12101217190629.shtml",
    "datetime": "2014-05-12 10:12:50",
    "code": "002099"
  },
  {
    "title": "海翔药业重大收购涉信披违规 重组方提前泄密",
    "href": "http://stock.jrj.com.cn/2014/05/07064117163243.shtml",
    "datetime": "2014-05-07 06:41:25",
    "code": "002099"
  },
  {
    "title": "海翔药业资产注入展开王云富高财技运作",
    "href": "http://stock.jrj.com.cn/2014/05/06113417158579.shtml",
    "datetime": "2014-05-06 11:34:34",
    "code": "002099"
  }
]